Galicaftor

N/A

Report date: 2023/06/23 20:01:31
NME

Base Information

Drug NameGalicaftor
Drug Alias NameGalicaftor - AbbVie/Galapagos NVABBV-2222GLPG-2222
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulators
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaUnited States +[14] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGalapagos NvAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesSionna Therapeutics IncAbbvie Inc
Inactive CompaniesGalapagos Nv
Active IndicationsN/A
Inactive IndicationsCystic Fibrosis

Other Information

ATC CodeN/A
Related LinksN/A